DEF: Firefly Neuroscience Seeks Shareholder Approval for Equity Issuances to Secure Funding

Firefly Neuroscience is requesting shareholder approval to issue more than 20% of its common stock to two entities, Helena Special Opportunities LLC and Arena Business Solutions Global SPC II, Ltd, to comply with Nasdaq listing rules and secure necessary financing.

Summary

• Firefly Neuroscience is holding a special meeting on February 14, 2025, to seek shareholder approval for two proposed equity issuances.
• The first proposal involves issuing more than 20% of the company's common stock to Helena Special Opportunities LLC, including upon conversion of a convertible note and exercise of a warrant, as part of a Securities Purchase Agreement dated December 20, 2024.
• The second proposal seeks approval to issue more than 20% of the company's common stock to Arena Business Solutions Global SPC II, Ltd, under a Purchase Agreement also dated December 20, 2024.
• These issuances are necessary to comply with Nasdaq Listing Rule 5635(d), which requires shareholder approval for transactions involving the issuance of 20% or more of a company's outstanding common stock at a price below the market average.
• The company entered into a Securities Purchase Agreement with Helena for a convertible promissory note of $2,400,000, including a $360,000 original issue discount, and a warrant to purchase 800,000 shares at $4.00 per share.
• The initial conversion price of the note is $3.00 per share, but it can adjust to 90% of the lowest daily VWAP if the company fails to secure $5,000,000 in financing within five months, with a floor price of $0.48.
• The company also entered into a Purchase Agreement with Arena for an equity line of credit of up to $10,000,000, with a commitment fee of $300,000.
• Under the Arena agreement, the purchase price for common stock will be 88% of the daily VWAP, and the company may not issue shares that would result in Arena owning more than 9.99% of the outstanding common stock.
• The company is also seeking approval to adjourn the special meeting if necessary to solicit additional proxies.

Sentiment

Score: 6

Explanation: The document is a standard proxy statement, which is neutral in tone. The proposed transactions are necessary for the company's financing, but they also carry risks of dilution for existing shareholders. Therefore, the sentiment is moderately positive.

Positives

• The proposed equity issuances could provide Firefly Neuroscience with necessary capital to fund operations.
• The equity line of credit with Arena provides a reliable source of capital for working capital and general corporate purposes.
• The company has the option to prepay the Helena note at any time after the issuance date, provided no Event of Default has occurred.

Negatives

• Existing shareholders will experience dilution in their ownership interests upon the issuance of new shares.
• The sale of new shares into the public market could negatively affect the market price of the company's common stock.
• Failure to obtain shareholder approval for the proposed issuances could result in the company incurring substantial additional costs and expenses.

Risks

• The conversion price of the Helena note could adjust to 90% of the lowest daily VWAP if the company fails to secure $5,000,000 in financing within five months, potentially leading to significant dilution.
• The company's ability to successfully implement its research and development plans is dependent on its ability to maximize capital raising opportunities.
• The company may need to seek alternative sources of financing if the proposed equity issuances are not approved, which may not be available on advantageous terms.

Future Outlook

The company's ability to preserve cash by repaying the Helena note through share issuances and to access capital through the Arena equity line of credit is contingent on shareholder approval of the proposed issuances.

Management Comments

• The Board has determined that the Purchase Agreement and our ability to issue shares of our common stock pursuant to the equity line thereunder in excess of the Exchange Cap is in the best interests of the Company and its stockholders as the Purchase Agreement provides us with a reliable source of capital for working capital and general corporate purposes.
• Our board of directors is not seeking the approval of our stockholders to authorize our entry into the Securities Purchase Agreement, as we already entered into the Securities Purchase Agreement on December 20, 2024.
• We are only asking for approval to issue to Helena, pursuant to the Securities Purchase Agreement, more than 20% of our issued and outstanding common stock as of December 20, 2024 (the date we entered into the Securities Purchase Agreement), including upon the conversion of the Note and upon exercise of the Warrant.

Industry Context

The need for shareholder approval for equity issuances is a common requirement for companies listed on the Nasdaq Capital Market, reflecting the importance of protecting shareholder interests while allowing companies to raise capital.

Comparison to Industry Standards

• The terms of the convertible note and equity line of credit are relatively standard for small-cap companies seeking financing.
• The conversion price adjustments and floor price provisions are common features in convertible notes to protect investors from significant price declines.
• The 88% of VWAP purchase price for the equity line of credit is a typical discount for such arrangements.
• The 20% threshold for shareholder approval is a standard requirement under Nasdaq Listing Rule 5635(d), which is designed to prevent excessive dilution without shareholder consent.
• Comparable companies in the biotech or neuroscience sector often utilize similar financing methods, including convertible notes and equity lines of credit, to fund their operations and research.

Stakeholder Impact

• Shareholders will experience dilution in their ownership interests if the proposals are approved.
• The company's ability to secure financing is dependent on shareholder approval.
• Employees and other stakeholders may be affected by the company's financial stability.

Next Steps

• Stockholders are urged to review the proxy statement and vote on the proposals.
• The company will hold a special meeting on February 14, 2025, to vote on the proposals.
• The company will file a Current Report on Form 8-K with the SEC to disclose the final voting results.

Key Dates

Keywords

equity issuance, shareholder approval, convertible note, warrant, equity line of credit, Nasdaq listing rule, dilution, financing, VWAP, common stock